Course book Advanced Treatment Planning 2018

Previous Page

Next Page

Page Background

Lung: what about low doses?

Khalil et al. Acta Oncol 2015: IMRT, LANSCLC, 87 cases

phase I (n=12)

only V20 < 40%

phase II (n=25)

V20 < 40%

and MLD ≤ 20 Gy.

phase III (n=50)

V20 < 40%

and MLD ≤ 20 Gy

and V5 ≤ 60%

24

without V5

with V5